Bharat Biotech’s Krishna Ella Leads Indian Vaccine Manufacturers: Krishna Ella, co-founder and executive chairman of Bharat Biotech, has been appointed as the new president of the Indian Vaccine Manufacturers Association (IVMA) for the next two years, starting April 2024. He takes over from Adar C. Poonawala, who held the position from 2019 until March 2024. This appointment is important for India’s vaccine industry.
Bharat Biotech’s Krishna Ella Leads Indian Vaccine Manufacturers
Ella’s role will involve leading efforts to promote and regulate vaccine production in the country. With his expertise, he aims to improve vaccine accessibility, quality, and affordability. Ella’s leadership at Bharat Biotech, known for developing Covaxin, India’s first indigenous COVID-19 vaccine, is expected to bring valuable insights to IVMA and further strengthen India’s position as a key player in global vaccine manufacturing.
| Join Telegram |  |
| Join Whatsapp Groups |  |
Leadership Responsibilities and Priorities
For the current two-year term, the IVMA has appointed the following key roles:
- Vice President: Mahima Datla, who is the Managing Director of Biological E.
- Treasurer: T. Srinivas, who serves as the CFO of Bharat Biotech.
- Director General: Dr. Harshavardhan (continuing his role).
Ensuring Fair Access to Vaccines
In a statement, Ella stressed the crucial role of vaccines in global health and the IVMA’s mission to make sure that everyone, no matter where they live, can get life-saving vaccines. He emphasized the importance of innovation, sustainability, and fairness as the core of their shared vision.
“I’m happy to work with IVMA’s esteemed members and help achieve its goal of safeguarding and improving public health in India and other developing nations,” Ella remarked.
Supporting Africa’s Public Health Goals
Ella encouraged IVMA members to support Africa’s public health goals and emphasized the importance of developing policies and regulations aligned with the World Health Organization (WHO) and the U.S. Food and Drug Administration (USFDA). He believes that this will make the industry more competitive globally and strengthen India’s vision to promote equal opportunities worldwide in preventive healthcare.
Recognizing Industry Contribution and IVMA’s Objective
Dr. Harshavardhan expressed confidence in Ella’s leadership, stating, “Ella’s skills and entrepreneurial drive are precisely what the vaccine industry requires to tackle the intricate challenges of the 21st century.”
The IVMA’s goal is to address the concerns of Indian private-sector human vaccine manufacturers regarding industry growth and profitability. It also aims to simplify regulatory processes, audits, and inspections in collaboration with the national Central Drugs Standard and Control Organization.
Follow Freshersnow.com for more data.
| You can Also Check |
| Current Affairs |